Content authored by practitioners with experience at Amazon India, Intuit QuickBooks, and the Tata Group. Meet the team →
Pharma manufacturers in India operate under NPPA / DPCO 2013 ceiling prices for scheduled drugs, PLI Pharma incremental-sales incentives across three product categories, Schedule M GMP batch-level traceability requirements, an R&D AP stream that must be ring-fenced from production AP for Section 35(2AB), formulation vs API segment accounting, expired and near-expiry stock buyback returns, GST complexities around online pharmacy aggregators under Section 9(5), and Section 393 TDS on API procurement and technical fees — each requiring its own reconciliation rail.
Tag every SKU as scheduled or non-scheduled at master setup with the active NPPA ceiling price; build a parallel PLI claim ledger keyed to eligible HSN / product code with base-year benchmark; enforce batch-level BOM-to-invoice trail at GRN under Schedule M; ring-fence R&D AP via a separate cost centre with DSIR tagging; run formulation and API as distinct segments with intercompany pricing controls; reconcile expired-stock returns to original sale invoice; treat Section 9(5) online pharmacy aggregator sales as e-commerce supplies; map Section 393(1)(b)/(k)/(a) TDS deductions to per-vendor counters with monthly challan reconciliation.
Pharma configuration with NPPA scheduled-drug master, PLI Pharma category tags (Cat 1/2/3), Schedule M batch-trace flag on every BOM line, R&D cost centre and DSIR approval flag, formulation vs API segment code, expired-stock return reason codes (near-expiry, full-expiry, regulatory recall), Section 9(5) e-commerce aggregator flag on customer master, Section 393 TDS code map per vendor type, distributor and stockist margin slab per scheduled SKU.
A monthly pharma close where scheduled SKU invoices stay within the NPPA ceiling backed by margin calculation; the PLI Pharma annual claim file ties to invoice-level eligible sales; every batch QC release ties to its BOM-to-invoice trail under Schedule M; R&D AP rolls up cleanly into the Section 35(2AB) weighted deduction claim; formulation and API segment P&Ls reconcile to a consolidated trial balance; expired-stock returns tie to original sale invoice with proportionate ITC reversal; Section 9(5) e-commerce supplies are tagged for aggregator GST treatment; Section 393 TDS deductions tie to monthly challans and quarterly returns.
A generic pharmaceutical manufacturer in Hyderabad operates four production sites — two formulation plants in Telangana, one API plant in Andhra Pradesh, and one packaging unit in Sikkim — with ₹250 crore annual revenue, 38% of it from NLEM-scheduled drugs under DPCO 2013, ₹46 crore from PLI Pharma Category 2 (APIs) on incremental sales above the base year, and a residual export book of ₹62 crore. The finance team’s monthly close ties together NPPA ceiling-price compliance, PLI Pharma claim accruals, Schedule M batch-level traceability, R&D cost segregation under Section 35(2AB), formulation vs API segment P&L, distributor and expired-stock returns, GST on online pharmacy aggregator supplies, and Section 393 TDS on API procurement and clinical-trial fees. This guide walks each rail and ties them back to the broader manufacturing reconciliation India framework.
Quick reference
| Item | Regulator / Scheme | Key threshold or rate |
|---|---|---|
| NPPA ceiling prices | NPPA under DPCO 2013 | MRP cannot exceed notified ceiling + permitted local taxes |
| PLI Pharma | Department of Pharmaceuticals | ₹15,000 Cr outlay, 3 categories, disbursed on incremental sales |
| Schedule M GMP | Drugs and Cosmetics Rules | Batch-level traceability for all formulations / APIs |
| R&D weighted deduction | Section 35(2AB) (transitioned) | DSIR-approved in-house R&D, weighted deduction on eligible spend |
| Online pharmacy aggregator | Section 9(5) CGST Act | Aggregator collects and pays GST as e-commerce operator |
| Technical / medical service TDS | Section 393(1)(b), code 1003 | 10% on professional and technical fees |
| Purchase TDS | Section 393(1)(k), code 1012 | 0.1% above ₹50 lakh per PAN per year |
| Contractor / toll-manufacturing TDS | Section 393(1)(a), code 1002 | 1% individual/HUF, 2% company/firm |
| GST on pharmacy / formulations | CGST Act | 5% / 12% / 18% depending on HSN; concessional rates for essential drugs |
Rail 1 — NPPA / DPCO 2013 price-ceiling reconciliation
The NPPA notifies ceiling prices for scheduled formulations listed in the NLEM. For every scheduled SKU a pharma manufacturer sells, the maximum retail price (MRP) cannot exceed the NPPA ceiling plus permitted local taxes. AP reconciliation reverses this: starting from the NPPA ceiling, the team works backwards through retailer margin (typically 20%), wholesaler / distributor margin (8-10%), GST (5% on most NLEM scheduled drugs, 12% on some, 18% on others), trade discount, and net realisation to ensure the invoice price at which the manufacturer sells to its stockists is consistent with the NPPA ceiling at the retail end. Overcharging — even by ₹0.50 per strip — across a high-volume scheduled SKU triggers a Drugs Prices Equalisation Account deposit obligation with interest, plus enforcement risk. The reconciliation control is a parallel “NPPA compliance ledger” that holds, for every scheduled SKU, the current ceiling price, the calculated permissible stockist price, the actual invoice price, and the variance — with any variance above zero routed to a regulatory exception queue.
Rail 2 — PLI Pharma claim reconciliation
PLI Pharma, with a total outlay of ₹15,000 crore, is administered by the Department of Pharmaceuticals across three product categories: Category 1 (biopharmaceuticals, complex generic drugs, patented drugs, orphan drugs), Category 2 (APIs, key starting materials, drug intermediates) and Category 3 (in-vitro diagnostic devices and other drugs not covered in Categories 1 and 2). Incentives are disbursed annually on incremental sales above a base-year benchmark, at rates that step down over the scheme period. The reconciliation rail builds an annual claim file tying invoice-level sales of eligible products to base-year sales, with HSN / product code mapping confirmed by the Project Management Agency, and a separate reconciliation ties the disbursement received from DoP against the approved claim — disbursements often arrive 6-12 months after claim filing, creating a long-running receivable to track and disclose under Ind AS 20.
Rail 3 — Schedule M GMP batch-level reconciliation
Schedule M of the Drugs and Cosmetics Rules mandates GMP requirements at all formulation and API plants. The AP and inventory rails inherit Schedule M’s traceability requirement: every batch of finished formulation must trace to its API lot, excipient lots, packaging components, and QC release record. Each batch of finished goods must reconcile to (a) the BOM consumption of APIs and excipients, (b) the GRN and invoice of those input lots, and (c) the QC pass/fail record. A batch released without a complete BOM-to-invoice trail is a Schedule M finding, not just an accounting gap, and creates risk in any subsequent regulatory inspection (CDSCO, USFDA for export-grade plants, MHRA for UK exports).
Rail 4 — R&D vs production AP segregation
R&D expenses qualify for weighted deduction under Section 35(2AB) of the Income Tax Act 2025 (transitioned from the legacy regime) for in-house R&D approved by DSIR. AP reconciliation must tag every invoice — clinical trial CRO fees, lab consumables, reference standards, animal study fees, regulatory filing fees, patent agent fees — to R&D or to production at the point of GRN. GST ITC eligibility differs: R&D consumables generally claim ITC; clinical-trial CRO fees often follow Section 17(5) rules depending on contract structure. Mis-tagging an R&D invoice as production inventory inflates COGS and understates the Section 35(2AB) weighted deduction claim — a permanent tax cost. The reconciliation control is a separate R&D cost centre tag at PO creation, carried through GRN and invoice booking, with quarterly roll-up reconciled against the DSIR Form 3CL claim file.
Rail 5 — Formulation vs API segment accounting
A vertically integrated pharma running both API and formulation plants must operate them as separate segments with intercompany pricing under Section 92 (transfer pricing) when the units are separate legal entities, or as internal divisions with arms-length internal transfer pricing controls when they are within a single entity. Reconciliation runs intercompany API supply against an arms-length benchmark, with the segment P&L produced monthly and reconciled to the consolidated trial balance.
Rail 6 — Distributor and expired-stock returns reconciliation
Expired and near-expiry stock returned by distributors creates a four-way reconciliation: (a) the original sale invoice and its NLEM / non-NLEM status, (b) the return note from the distributor with reason code (near-expiry, full-expiry, regulatory recall), (c) the proportionate GST credit note under Section 34 of the CGST Act with ITC reversal in the distributor’s books, and (d) the inventory destruction certificate if the stock is destroyed. Online pharmacy aggregators (1mg / Tata 1mg, Pharmeasy, Apollo Pharmacy, NetMeds) — where Section 9(5) of the CGST Act may apply for specified services — add a further reconciliation layer because the e-commerce operator is liable to collect and pay GST on certain supplies, changing the manufacturer-side invoicing flow for those channel sales.
Rail 7 — Section 393 TDS
Section 393(1)(b), code 1003 (replaces 194J) — applies at 10% on technical or medical service fees, common for clinical trial principal investigator fees, medical advisory retainers, and certain CRO scopes. See Section 393 TDS new Income Tax Act reconciliation.
Section 393(1)(k), code 1012 (replaces 194Q) — applies at 0.1% on resident-vendor purchases above ₹50 lakh per PAN per year, where buyer turnover crossed ₹10 crore in the preceding year — relevant for high-value API procurement. Detail at manufacturing 393(1)(k) purchase goods reconciliation.
Section 393(1)(a), code 1002 (replaces 194C) — applies on contract manufacturing and toll-blending arrangements. Cross-era reconciliation against Form 26AS data filed before 1 April 2026 needs the legacy 194C reference.
Worked example: ₹250 Cr pharma quarterly close
A generic pharma manufacturer in Hyderabad closes Q2 FY26-27 with ₹62.5 crore quarterly revenue. Across the rails: 87 scheduled SKUs covered by NPPA ceilings with zero overcharging variance; PLI Pharma Category 2 (API) incremental-sales accrual of ₹3.8 crore awaiting DoP approval; 412 production batches QC-released under Schedule M with full BOM-to-invoice trail; R&D AP of ₹4.2 crore booked to a separate cost centre with DSIR Form 3CL claim file in preparation; intercompany API supply from the API plant to the formulation plant valued at ₹14.6 crore at arms-length benchmark; distributor returns of ₹68 lakh across 142 batches reconciled to original sale invoices with GST credit notes issued; online pharmacy aggregator channel sales of ₹2.8 crore tagged under Section 9(5); Section 393(1)(k) purchase TDS deductions of ₹22 lakh across 9 API vendor PANs; Section 393(1)(b) clinical-trial fees TDS of ₹14 lakh; Section 393(1)(a) toll-manufacturing TDS of ₹6 lakh. Total reconciliation lines across seven rails: about 5,800.
What automated reconciliation changes
Pharma finance teams running these seven rails on spreadsheets typically lose 40-60% of one finance FTE per month to NPPA compliance back-calculation and PLI claim file preparation alone. Purpose-built reconciliation software India configured with the pharma preset carries the NPPA scheduled-drug master, the PLI category tags, the Schedule M batch-trace requirement, the R&D cost centre flag, the formulation/API segment split, the Section 9(5) e-commerce flag, and the Section 393 TDS code map out of the box. Customer outcomes include match-rate improvement from 51% to 88% on the procurement rail, with the NPPA compliance ledger and PLI claim file producing audit-ready outputs in days rather than weeks. Build is two-to-four weeks on AWS Mumbai (ISO 27001:2022). For the authoritative current text of NPPA ceiling notifications, the National Pharmaceutical Pricing Authority portal is the source. For the headline three-way match rail see three-way matching software India.